Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Fischer, Kirsten; Al‐Sawaf, Othman; Bahlo, Jasmin; Fink, Anna Maria; Tandon, Maneesh; Dixon, Mark; Robrecht, Sandra; Warburton, Simon; Humphrey, Kathryn; Samoylova, Olga; Liberati, A. M.; Pinilla‐Ibarz, Javier; Opat, Stephen; Sivcheva, Lylia; Dû, Katell Le; Fogliatto, Laura; Niemann, Carsten Utoft; Weinkove, Robert; Robinson, Sue; Kipps, Thomas J.; Böettcher, Sebastian; Tausch, Eugen; Humerickhouse, Rod; Eichhorst, Barbara; Wendtner, Clemens‐Martin; Langerak, Anton W.; Kreuzer, Karl; Ritgen, Matthias; Goede, Valentin; Stilgenbauer, Stephan; Mobasher, Mehrdad; Hallek, Michael

doi:10.1056/nejmoa1815281

Cited by 614 publications

(640 citation statements)

References 28 publications

Supporting

Mentioning

608

Contrasting

Unclassified

Order By: Relevance

“…Venetoclax combined with obinutuzumab has also been proven superior to obinutuzumab combined with chlorambucil in treatment-naïve unfit patients. 42 However, it should be noted that the time spent in the clinic and resource utilization with venetoclax in the ramp-up phase are greater than with ibrutinib. In the relapsed setting, both drugs have shown excellent results 43,44 and are currently considered the standard of care.…”

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 99%

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Perini

Fischer

Gaiolla

et al. 2020

Hematology, Transfusion and Cell Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 99%

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Perini

Fischer

Gaiolla

et al. 2020

Hematology, Transfusion and Cell Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Venetoclax is a potent, selective and orally bioavailable small‐molecule inhibitor of the anti‐apoptotic protein B‐cell lymphoma 2 (BCL2) with high efficacy in treatment‐naïve (Fischer et al, ) and relapsed or refractory (R/R) CLL including TP53 ‐disrupted disease (Stilgenbauer et al, ). Phase II trials demonstrate impressive activity in these settings with an overall response rate (ORR) of c .…”

Section: Treatment Complications Comparing Age Categoriesmentioning

confidence: 99%

“…Venetoclax is a potent, selective and orally bioavailable small-molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2) with high efficacy in treatment-na€ ıve (Fischer et al, 2019) and relapsed or refractory (R/R) CLL including TP53-disrupted disease (Stilgenbauer et al, 2016). Phase II trials demonstrate impressive activity in these settings with an overall response rate (ORR) of c. 80% in the B-cell receptor inhibitor (BCRi)-na€ ıve setting (Stilgenbauer et al, 2016) and high response rates (65-67%) post-BCRi (Jones et al, 2017;Coutre et al, 2018).…”

mentioning

confidence: 99%

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

et al. 2019

View full text Add to dashboard Cite

Summary Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B‐cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and <75 years treated in the relapsed, refractory non‐trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib‐exposed and therefore may otherwise have few clear therapeutic options.

show abstract

“…Several novel oral targeted therapies are now available, including ibrutinib, acalabrutinib, and venetoclax. The choice of targeted therapy depends on several patient-and disease-related factors [45][46][47][48][49][50]. Ibrutinib and acalabrutinib generally require fewer clinic/laboratory visits at the time of treatment initiation compared with the venetoclax + obinutuzumab regimen.…”

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 99%

Treating Leukemia in the Time of COVID-19

et al. 2020

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton's tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 highrisk periods. The knowledge about COVID-19 is accumulating rapidly. An important distinction is the prevalence of "exposure" versus "clinical infectivity," which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of clinical infection is < 1-2% worldwide. With a mortality rate of 1-5% in CO-VID-19 patients in the general population and potentially of > 30% in patients with cancer, careful consideration should be given to the risk of COVID-19 in leukemia. Instead of reducing patient access to specialized cancer centers and modifying therapies to ones with unproven curative benefit, there is more rationale for less intensive, yet effective therapies that may require fewer clinic visits or hospitalizations. Here, we offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods.

show abstract

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Cited by 614 publications

References 28 publications

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Treating Leukemia in the Time of COVID-19

Contact Info

Product

Resources

About